You just read:

Tocagen Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Toca 511 & Toca FC in Recurrent High Grade Glioma

News provided by

Tocagen Inc.

23 Feb, 2017, 08:00 ET